About DermBiont
DermBiont is a private company based in Boston, Massachusetts. It has reported $86,962,227 raised in seven offerings on Form D since June 2019. Its chief executive is Karl Beutner.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 4, 2023 | Oct 19, 2023amended Nov 13, 2024 | $32,697,081of $45.3M target | 72 | $454K | Equity, OptionsRule 506(b) | Form D/A ↗2 earlier filings |
| Mar 6, 2023 | Mar 21, 2023 | $4,693,564fully sold | 69 | $68,023 | DebtRule 506(b) | Form D ↗ |
| Sep 6, 2022 | Sep 19, 2022 | $2,514,010target not set | 11 | $228K | DebtRule 506(b) | Form D ↗ |
| Dec 17, 2021 | Dec 29, 2021 | $28,845,632of $39.5M target | 42 | $686K | EquityRule 506(b) | Form D ↗ |
| Feb 12, 2021 | Feb 24, 2021 | $6,550,582of $15.0M target | 19 | $344K | Debt, OptionsRule 506(b) | Form D ↗ |
| Feb 19, 2020 | Mar 4, 2020 | $2,871,893of $6.0M target | 14 | $205K | DebtRule 506(b) | Form D ↗ |
| May 31, 2019 | Jun 11, 2019 | $8,789,465fully sold | 42 | $209K | EquityRule 506(b) | Form D ↗ |
| Total, seven offerings | $86,962,227 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on DermBiont's Form D filed Nov 13, 2024.
DY
SB
Steven Basta
Director
KB
Karl Beutner
Chief Executive Officer and director
Also an executive officer and director at Rinascera Therapeutics.
NE
Nichola Eliovits
Executive officer and director
Also a director at MaverickX and Phoenix Tailings and a chief executive officer and director at Rinascera Therapeutics.
MD
WR
Wilder Ramsey
Director
Earlier filings also listed Jennifer Lee (director, last listed Mar 2023) and Robert Brucker (executive officer, last listed Aug 2021).